The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Clinical trial NCT02962388 · TERMINATED
Trial details
- NCT number
- NCT02962388
- Sponsor
- French Innovative Leukemia Organisation
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-03
- Primary completion
- 2021-06-28
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.